Trial Profile
A Prospective Trial of Revlimid in Transfusion Dependent Patients With Non-del (5q) Low/Intermediate-1 Risk Myelodysplastic Syndrome.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 30 Jul 2021 Planned End Date changed from 1 Mar 2021 to 1 Jan 2022.
- 12 Mar 2019 Planned End Date changed from 1 Sep 2016 to 1 Mar 2021.
- 12 Mar 2019 Planned primary completion date changed from 1 Sep 2016 to 1 Feb 2020.